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Hyperlipidemia is the impairment of lipid metabolism marked by abnormally high levels 
of lipid in circulation. This has been implicated in a number of metabolic diseases 
including diabetes, cardiovascular diseases, and nonalcoholic fatty liver disease. Insulin 
resistance is the impairment of insulin action, which leads to several diseases such as 
obesity and type 2 diabetes. New clinical and therapeutic approaches are warranted for 
the prevention and treatment of hyperlipidemia and insulin resistance. In our study, we 
investigated the mechanism underlying the effect of complete disruption of the sub-
diaphragmatic vagus nerve (vagotomy) on hyperlipidemia and insulin sensitivity. We 
observed that vagotomy significantly reduced the fasting and postprandial TG levels and 
VLDL synthesis. Vagotomy also resulted in elevated circulatory GLP-1 levels which 
possibly led to reductions in de novo fatty acid synthesis and VLDL production. This 
surgical procedure also found to ameliorate HFD-induced hyperlipidemia and hepatic 
steatosis. Significant improvement in insulin sensitivity was also observed in 
vagotomized mice. We also studied the effect of fenugreek seeds on hyperlipidemia using 
CREBH-null mouse model. We observed that consumption of fenugreek and treatment 
with trigonelline, a bioactive compound derived from fenugreek, ameliorated induced 
hyperlipidemia by upregulating transcription of Insig proteins, preventing VLDL 
synthesis and enhancing fatty acid oxidation. These findings rationalize the use of 
vagotomy as an effective clinical procedure to treat obesity and diabetes. The study also 
substantiates the prospect of using fenugreek as a potent nutraceutical in the treatment of 
metabolic diseases.
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Chapter One: General Introduction 
1.1 Hyperlipidemia 
Hyperlipidemia, an impairment of lipid metabolism marked by an abnormal elevation of 
lipid in blood plasma, is rapidly increasing around the world [1]. It is linked to the 
pathogenesis of myriads of chronic metabolic diseases such as nonalcoholic fatty liver 
disease (NAFLD), insulin resistance and atherosclerosis [2]. Hyperlipidemia involves 
elevated serum total cholesterol (TC), triglycerides (TG), and low –density lipoprotein 
cholesterol (LDL-C) and decreased levels of high-density lipoprotein cholesterol (HDL-
C) [3]. Increased LDL-C in circulation is considered a high risk factor of atherosclerosis 
(AS) and coronary heart disease (CHD). Elevated levels of circulatory triglycerides (TG) 
and free fatty acids (FFA) also contribute to AS and CHD.  High prevalence of 
hyperlipidemia is intrinsically linked to increased risks of cardiovascular diseases (CVD) 
[1]. It is imperative to devise strategies to modulate the dysregulation of lipid metabolism 
and reduce the levels of blood TC, TG and LDL-C in order to ameliorate CVD. Lipid- 
lowering drugs like statins, fibrates, and nicotinic acid, are normally prescribed for 
treating hyperlipidemia. However, these drugs have limitations due to side effects and 
poor tolerability in some patients [3].    
CREBH, c-AMP responsive-element- binding protein H, is associated with 
hyperlipidemia. The CREBH, encoded by CREB3L3 gene in human, is an ER-bound 
transcription factor expressed extensively and exclusively in the liver and small intestine 
[4].  It belongs to the CREB/ATF family, and consists of a basic leucine zipper (bZIP) 
domain and a transmembrane domain [5, 6]. Proteolytic cleavage between the bZIP 
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domain and the transmembrane domain releases the ER membrane-bound CREBH 
protein which then translocate to the nucleus for transcriptional regulation of target genes 
[7, 8]. It was later reported that ER stress is responsible for expression and cleavage of 
CREBH protein via response intramembrane proteolysis (RIP) in the hepatocytes [9]. 
Besides, bacterial endotoxin lipopolysaccharides and proinflammatory cytokines such as 
TNF-, IL-6 and IL1β can also lead to expression and activation of CREBH. Nutritional 
cues such as fasting and fatty acid can induce CREBH expression and refeeding 
suppresses the expression [2, 4, 6]. These transcription factors have been found to be 
involved in glucose and lipid metabolism [5, 10, 11]. 
Disruption of the CRE3L3 gene, which encodes CREBH, expression leads to disorders in 
lipid metabolism. Nonsynonymous mutations in CREB3L3 gene was reported to develop 
non-functional CREBH, which led to extreme hypertriglyceridemia in mice suggesting a 
significant role of CREBH in triglyceride metabolism [4]. In another study, atherogenic 
high fat diet fed CREBH-null mice showed hepatic lipid accumulation and increased 
plasma TG levels indicating a crucial role of CREBH in maintaining hepatic lipid 
homeostasis [5]. Other studies also emphasize the role of CREBH in the regulation of 
plasma TG levels which suggest CREBH as an antiatherogenic transcription factor [10, 
11].  Studies have also established a link between CREBH expression, metabolic 
inflammation, VLDL metabolism, and hyperlipidemia [12]. Therefore, reduced levels of 
CREBH is one of the major factors associated with hyperlipidemia. 
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1.2 Insulin Resistance:  
 Insulin is an endocrine hormone secreted by pancreatic β-cells in response to nutrients 
uptake, primarily glucose. The secretion of insulin, however, is also augmented by free 
fatty acids and amino acids in circulation. [13]. Insulin is the primary hormone of energy 
homeostasis as it stimulates influx and utilization of glucose in the muscle, glycogen 
synthesis in the liver and muscle, fat storage in the adipocytes, and suppression of hepatic 
glucose uptake [14-17]. Insulin action involves an intricate set of signals which enables 
the body to balance nutrient availability and requirements [17]. 
Insulin resistance (IR) refers to impaired insulin action manifested by a decreased 
response of the peripheral tissues to a certain concentration of insulin [18, 19].  This 
pathological condition leads to several disease states, including hypertension, glucose 
intolerance, obesity, dyslipidemia, type 2 diabetes, low HDL cholesterol, and accelerated 
atherosclerosis [18, 20]. IR may develop in different organs like the liver, muscle, kidney, 
adipose tissue and pancreas [21]. The lack of insulin action leads to increased hepatic 
glucose production, decreased glycogen synthesis, and reduced glucose uptake by 
muscle, resulting in increased levels of glucose in circulation which is the well-
recognized feature of IR [14, 21]. 
 The exact reason for IR still remains unclear despite different postulations aimed to 
elucidate the underlying mechanism [22]. Nevertheless, some of the contributing factors 
include impaired insulin receptor substrate (IRS) and glucose transporter protein 
(GLUT), β-cell dysfunction, phosphorylation of intracellular glucose, oxidative stress, 
free fatty acids and adipokines [21, 23]. Free fatty acids (FFA) have been widely 
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considered as a critical factor in development of IR [17, 23, 24]. FFA may induce IR by 
impairing glucose transporter (GLUT), a protein that mediated translocation of glucose 
into muscle [25]. Proinflammatory adipokines, such as TNFα and IL-6, released by 
obesity-induced hypertrophic adipocytes may also induce insulin resistance by turning 
the insulin signaling down via serine phosphorylation of IRS-1 [25-28]. In the absence of 
insulin regulation, the flux of FFA from adipocytes to other tissues such as hepatocytes, 
pancreas and muscle tissue is augmented via increased lipolysis. This further deteriorates 
insulin activity and leads to other adverse effects such as lipotoxicity [28]. 
1.3 Vagus Nerve Signaling and GLP-1 Secretion:   
The vagus nerve is the principal nerve of the parasympathetic nervous system, one of the 
three divisions of the autonomic nervous system [29]. The afferent and efferent signaling 
of the vagus nerve plays an important role in the regulation of feeding behavior and 
metabolic homeostasis [29]. Abdominal vagal efferent activity regulates secretion of 
gastric and pancreatic digestive juices and anabolic hormones [30]. Vagotomy is the 
surgical removal of the vagus nerve. Sub-diaphragmatic vagotomy reportedly reduced 
obesity and improved fasting insulinemia, glucose tolerance and insulin sensitivity in 
monosodium glutamate-treated (MSG) mice [31, 32]. However, the underlying 
mechanisms are still not elucidated.   
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted in the intestine in 
response to food intake and hormone regulation [33, 34]. Among all other nutrients, 
glucose and monounsaturated fatty acids are the primary stimulus of GLP-1 secretion 
[35]. GLP-1 is synthesized by the enteroendocrine L cells of ileum and proximal colon 
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[36, 37].  GLP-1 is also synthesized in the brain as a neuropeptide where it contributes to 
central regulation of metabolic and cardiovascular functions [38, 39]. These peptides are 
implicated in glucose-dependent insulin secretion, glucagon inhibition, gastric emptying, 
and enhanced satiety [34, 36, 37, 39, 40, 41, 42, 43]. Besides, GLP-1 modulates β-cell 
apoptosis, activates hepatoportal glucose sensors, and promotes β-cell growth and 
preservation, and peripheral insulin sensitivity [44- 47]. Moreover, GLP-1 action 
attenuates postprandial secretion of large, triglyceride containing lipoproteins in plasma 
[36, 42]. Native GLP-1 has also been found to prevent development of atherosclerotic 
lesions [48, 49]. Recent studies reported the potential role of these incretin peptides in 
recruitment of muscle vasculature, augmented delivery of insulin to muscle, and 
improvement of insulin action in insulin-resistant states [50].  
Stearoyl-CoA desaturase (SCD) participates in the de novo synthesis of monounsaturated 
fats from saturated fatty acids. One of the major products of this conversion is oleate 
which is the major monounsaturated fatty acid of phospholipids of the bi-layered 
membrane, triglycerides, cholesterol esters, wax esters, and diacylglycerol. Two SCD 
isoforms viz., SCD-1 and SCD-2 have been identified in humans. Adipose and liver 
tissues express highest levels of SCD-1 expression, while SCD-2 is primarily expressed 
in brain and pancreatic tissues [51]. Although no protection from obesity was observed, 
simultaneous deletion of SCD-1 in liver and adipose tissues reportedly lowered TG levels 
in the liver and improved glucose tolerance [52]. It has also been established that there is 
a relation between SCD-1 mRNA expression and 16:1/16:0 activity indices in plasma 
VLDL-TG [53]. Keeping these observations in view, SCD-1 mRNA expression can 
possibly be used as a reliable tool to assess alterations in lipid metabolism in the liver. 
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1.4 Fenugreek: 
Fenugreek (Trigonella foenum-graecum L.) is an annual crop that belongs to 
Leguminosae family. Fenugreek has mostly been used as a spice in various parts of the 
world to improve the sensory quality of food [54]. This crop is widely cultivated in most 
regions of the world, particularly in India, Pakistan, China, Egypt, Ethiopia, Morocco and 
England [55-57].  
Fenugreek seeds are used in India and other Asian countries as a spice in food 
preparations owing to their strong aroma and flavor [58, 59]. The leaves are also 
consumed in India as a green, leafy vegetable as they are a rich source of calcium, iron, 
β-carotene and other vitamin content [60]. Besides, the extract of fenugreek is used as a 
flavoring agent to make cheese in Switzerland, artificial maple syrup and bitter-run in 
Germany, as substitute to coffee in Africa, as fortification to make bread in Egypt, anti-
diabetic herb in Israel, as insect and pest repellent in grain storage in France [56,60]. 
Fenugreek is used as herbal medicines in many regions of the world [60]. They have long 
been used in traditional Ayurvedic, Unani and Chinese medicinal systems for treatment 
of numerous human health problems like diabetes, indigestion, epilepsy, paralysis, gout, 
chronic cough, and as a general oral medicine to improve metabolism [57, 59, 61]. 
Several important chemical compounds of medicinal value have been identified in 
fenugreek leaves and seeds. Fenugreek has been recognized among common 
nutraceutical products because of the presence of three important chemical constituents. 
The seeds are a good source of important steroidal sapogenin like diosgenin, the 
polysaccharide galactomannans, and isoleucine. Fenugreek is known to have several 
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pharmacological properties such as hypoglycemic, hypocholesteorolemic, antioxidant, 
anti-inflammatory, and anti-ulcerogenic [55, 59, 62]. The amino acids histidine and 
hydroxyisoleucine in fenugreek reportedly plays a key role in insulin sensitivity [63]. 
Optimal consumption of fenugreek has been reported to reduce triglycerides and 
cholesterol levels in plasma [64]. Study with ethyl acetate extract of fenugreek seeds 
showed lowered LDL-triglycerides and cholesterol and increased HDL-cholesterol [65]. 
The findings in these reports indicate that bioactive compounds in fenugreek seed are 
possibly involved in lipid metabolism.  
Trigonelline is a natural plant alkaloid which was first isolated from fenugreek seeds [66, 
67]. This bioactive compound is known to possess hypoglycemic and hypolipidemic 
properties [67]. Trigonelline is highly regarded as an anti-diabetic owing to its ability to 
improve insulin sensitivity by enhancing insulin signaling [68] and by ameliorating ER 
stress and oxidative stress-mediated pancreatic cell damage [67], increased insulin 
secretion, inhibit adipogenesis, upregulate antioxidant enzyme activity, decrease lipid 
peroxidation, and prevent postprandial hyperglycemia [66-70]. Trigonelline has also been 
reported to possess inhibitory effects on cancer and non-alcohoic fatty liver diseases 
(NAFLD) [71, 72].  
1.5 Working Hypothesis 
We hypothesize that vagotomy leads to alteration in the levels of glucagon-like peptide-1 
(GLP-1), which in turn inhibits hepatic very low density lipoprotein (VLDL) assembly 
and secretion, leading to the amelioration of hyperlipidemia and insulin resistance 
induced by high-fat-diet (HFD). Consumption of fenugreek seeds also modulates hepatic 
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VLDL secretion and improves insulin sensitivity by modulating the expression of genes 
involved in fatty acid metabolism and β-oxidation, and alleviating ER stress-induced 
inflammation.  
1.6 Study Objectives: 
Aim-1: The goal of this study is to assess the role of GLP-1 in modulation of lipoprotein 
metabolism in vagotomy mice. We will first investigate the role of GLP-1 in modulation 
of hepatic lipid metabolism. We will further study any possible impact of vagotomy on 
insulin sensitivity and glucose tolerance.     
Aim-2: In aim-2, we will elucidate the role of fenugreek seeds in regulation of de novo 
lipid synthesis and further investigate the effect of the bioactive compound trigonelline 
on hyperlipidemia.  
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Chapter Two: Materials and Methods 
2.1 Animals and Animal Experiments: 
For in vivo studies, 12-week old sham and vagotomized (sub-diaphragmatic) mice were 
purchased from Jackson Laboratory (Bar Harbor, Maine, USA). Animals were housed 
under alternating 12 h light and dark conditions with unrestricted access to food and 
water. All the mice were placed on a chow diet (Dyets Inc., USA). Animals were used for 
specific experiments following a week of acclimatization. Baseline blood was collected 
from the animals after a 12 h fast. In order to use for high fat feeding studies, animals 
were fed a regular chow diet ad libitum or a high fat diet (HFD) (11.5% coconut oil, 
11.5% corn oil, 5% fructose, and 0.5% cholesterol) (Purina Rodent Chow no. 5001, 
#C11953; Research Diets, New Brunswick, NJ, USA) for 22 weeks. Body weight, food 
intake, and plasma lipids were monitored throughout the feeding period. After 22 weeks 
of HFD feeding, tissues were collected from the animals following a 5 h fasting and 
subsequent anesthetization using isoflurane (3% mixed with oxygen). The tissues were 
snap frozen in liquid nitrogen and stored at -80% for future experiments.          
For studies with fenugreek, 10-14 week old CREBH knockout mice, with deletion of 
exons 4-7 of the CrebH gene, were used [5, 9]. The animals were housed with alternating 
12-hour light and dark cycles with free access to food and water and placed on a standard 
chow diet (Envigo, Madison, Wisconsin. #2016). CREBH-null mice were randomly divided 
into two groups (n=10/group) and given either a standard chow with vehicle (Nutriacal 
gel, Vetoquinol, Princeville, Quebec) or chow containing 2% of fenugreek whole seed for 
7 weeks. The fenugreek seeds (cultivar Tristar) were provided by Dr. Dipak Santra 
(Panhandle Research and Extension Center, University of Nebraska-Lincoln). Fenugreek 
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was grown in Research Farm of Panhandle Research and Extension Center at Scottsbluff, 
NE (41.890746, -103.676169) under irrigation in 2014 growing season. After completion 
of the 7 weeks feeding procedure, the mice were euthanized by isoflurane (3% mixed 
with oxygen) following 12 h of fasting. Blood samples from the heart were collected in 
lithium heparin coated capillary tubes (BD Vacutainer Labware Medical, USA). Plasma 
from the blood samples were separated by spinning at 6000 rpm at 4oC for 10 min, and 
were stored at -80oC for future analyses. The liver tissues were snap frozen in liquid 
nitrogen and stored at -80oC for further analyses.    
 
2.2 Cell Culture Treatments: 
For in vitro studies, rat hepatoma cell lines, McA-RH7777 (McA) (ATCC) cells were 
used, which were maintained in DMEM containing 10% FBS, 4.5 g/L glucose and 0.5% 
penicillin/streptomycin at 37°C, 5% CO2. The cells were cultured in flasks with media 
changes every alternate day and regularly passaged every 3-4 days. 3 x 106 cells were 
seeded onto 6-well plates 24 h prior to treatment. Palmitic acid (PA) was prepared as 
previously described [73]. The cells were subsequently treated with exendin-4 (Exenatide 
H-8730, Bachem, Bubendorff) (100 nm), palmitic acid (PA) (50 µM) or vehicle (0.5% 
BSA) for 48 h in DMEM devoid of FBS. Primary hepatocytes, isolated from 12-week old 
C57/B6 male mice, were seeded (1.3 x 106) onto 6-well plates and cultured in William’s 
R medium containing 5% FBS, 0.5% P/S, 1% L-Glutamine. Cells were then treated with 
exendin-4 (100 nM), PA or vehicle (0.5% BSA) for 48 h in William’s E medium without 
FBS. Media was collected for measuring secreted TG and CHOL.   
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For trigonelline treatment, 3 x 105 cells were seeded onto 6-well plates and maintained in 
complete DMEM (4.5g/L glucose). When the cells reached 60-70% confluence, they 
were treated with 100 μM of trigonelline (Sigma-Aldrich, St. Louis, MO) for 24 h 
followed by a 12 h fast. After the 12 h fasting, the cells were then treated with palmitic 
acids (PA) in the presence of mock (H2O) or trigonelline (100µM) for additional 6 h. The 
media were collected for lipid extraction and estimation as described in a previous 
publication. [74]    
 
2.3 RNA Expression Studies:  
Total RNA was extracted from the cryo-preserved livers of CREBH-null mice fed with 
chow diet along with 2% fenugreek seeds, as well as vagotomized and sham mice. The 
mRNAs from tissues were extracted with TRIzol reagent (Life Technologies, Grand 
Island, NY) according to the protocol provided by the manufacturer. Integrity of the 
isolated mRNAs was confirmed using a NanoDrop 2000 (Wilmington, DE). The mRNAs 
were reversed with a high capacity cDNA reverse transcription kit with RNase inhibitor 
(Life Technologies). The expression levels of peroxisome proliferator-activated receptor 
α (PPARα), carnitine palmitoyltransferase (CPT-1α), peroxisomal acyl-coenzyme A 
oxidase 1 (Acox-1), Insulin-induced gene 1 (Insig1a), insulin-induced gene 2b (Insig2b), 
medium-chain acyl-CoA dehydrogenase (MCAD), fatty acid synthase (FASN), acetyl 
CoA carboxylase (ACC), sterol regulatory element binding protein 1c and 2 (SREBP-1c 
and SREBP-2), and SCD-1  mRNA were measured by quantitative real-time PCR (qRT- 
PCR) using SYBR Green PCR Master Mix (Applied Biosystems, Life Technologies). 
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18S rRNA was used as an internal reference to calculate relative quantities of mRNA 
from threshold cycle (CT) values with the comparative CT method.  
2.4 Lipid Extraction and Lipid Content Measurements: 
To extract liver lipid, approximately 300 mg of liver tissue was added to 20 volumes of 
2:1 chloroform: methanol mixture and incubated at room temperature for 24 h. After the 
incubation, 0.2 volumes of 0.9% NaCl was added to the solvent mixture. The samples 
were centrifuged at 2000 rpm for 3 min following a thorough vortex. The upper aqueous 
layer was discarded and the volatile solvent layer was allowed to air dry. The dried lipid 
was resuspended in 1 ml of 100% ethanol. Lipid from cultured cells were extracted by 
3:2 hexane: isopropanol, dried and resuspened in 100% ethanol [46]. In order to study the 
alterations in lipid in circulation, 2 μl of plasma was used to measure the lipid contents. 
The levels of TG and CHOL were measured using an enzymatic/GPO lipid assay kit 
(Pointe Scientific, Canton, MI). The assay was done in accordance with the protocol 
provided by the manufacturer.   
2.5 Immunoblot Analysis: 
Proteins were extracted from the treated cells using 1x RIPA lysis buffer (150 mM 
sodium chloride, 10 mM Tris pH 7.4, 1mM EDTA, 1% Nonidet P-40, and protease 
inhibitor cocktail tablet). Protein samples were prepared with 4x SDS loading buffer (200 
mM Tris-HCL, pH 6.8, 8% SDS and 0.002% bromophenol blue) and separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After 
separation, proteins were transferred overnight onto polyvinylidene fluoride (PVDF) 
membranes (Millipore, Billerica, MA) under a voltage of 40V at 4oC in a wet transfer 
13 
 
 
apparatus (Bio-Rad Laboratories Ltd., Mississauga, ON). The membranes were blocked 
in 5% milk in 1X TBST for at least 2 hours on a shaker at room temperature. The 
membranes are then washed with 1x TBST 5 times for 5 minutes and were subsequently 
incubated with primary antibodies overnight at 4oC. The following antibodies were used 
for immunoblotting: anti-apoB, anti-apoE, and anti-albumin (Nittobo America Inc., 
Murrieta, CA); anti-β-actin (Sigma Aldrich, St. Louis, MO); anti-phospho-Akt, anti-
SCD-1, and anti-insulin receptor β (Cell Signaling, Danvers, MA); anti-SREBP-1c and 
anti-SREBP-2 (Novus, Littleton, CO). The final concentration of all the antibodies used 
was 0.1- 1 µg/ml). The membranes were washed 5 times for 5 minutes with 1X TBST the 
following day and incubated with specific horseradish peroxidase-conjugated IgG 
secondary antibodies. Anti-mouse, anti-rabbit (GE Healthcare, Buckinghamshire, UK), or 
anti-goat (Santa Cruz, Dallas, TX) IgG secondary antibodies were used in the study. The 
membranes were again washed in 1x TBST 5 times for 5 minutes and treated with 
Luminol enhancer solution for 2 minutes for detection by enhanced chemiluminescence 
(ECL) (Pierce, Rockford, IL). The proteins were visualized in FluorChem E system 
(Protein Simple, San Jose, CA). Protein bands were quantified using Image J (NIH). 
2.6 Oral Glucose Tolerance Test (OGTT): 
The mice were fasted for 12 h overnight prior to oral glucose tolerance test. The baseline 
blood glucose concentration was first measured via tail vein bleeding. The mice were 
then given glucose by oral administration appropriate to their body weight (2g/kg). Blood 
glucose concentrations were measured at 15, 30, 60 and 90 min after glucose 
administration using a handheld glucometer (Contour/Next, Beyer).  
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2.7 Lipoprotein Characterization: 
The lipoprotein subclasses in the plasma were separated using gel filtration fast protein 
liquid chromatography (FPLC). 150 µL plasma samples were injected onto a Superose 6 
10/200 GL column (Amersham Pharmacia Biotechnology, Piscataway, NJ). The flow 
rate of the whole process was 0.5 ml/min. Specific eluent was used to elute the different 
fractions from the column. The TG and CHOL contents in each of the fractions were 
subsequently measured. The recipe of the eluent is: 10 mM Tris, 150 mM NaCl, 2 mM 
CaCl2, 100 μM DTPA, 0.02% NaN3, pH 7.4.  
2.8 Plasma GLP-1 Measurement 
GLP-1 in plasma was analyzed the GLP-1 (active 7-36) ELISA kit (Cat # 43-GP1HU-
E01, Alpco Diagnostics, Salem, NH) according to the manufacturer’s instructions.  
2.9 Statistical Analysis: 
Data acquired in the experiments were evaluated using one-way ANOVA (GraphPad 
Prism 5, La Jolla, CA, USA). The two-tailed Student’s t-test was used for statistical 
analyses of two-group comparisons. All results are presented as mean ± SEM. Asterisks 
(* or **) indicate statistically significant differences of P < 0.05 or P < 0.01, 
respectively, compared to controls. 
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Chapter Three:  Results 
3.1 Vagotomy 
3.1.1 Sub-Diaphragmatic Vagotomy Reduces Circulatory TG and Protects Mice 
from Hyperlipidemia.  
To determine the effect of sub-diaphragmatic vagotomy on lipid metabomism, we first 
investigated fasted and fed (ad libitum) circulating lipid levels. There was a significant 
reduction in circulatory TG levels at both fasted and fed states in vagotomized mice as 
compared to sham mice. There were no significant changes in plasma CHOL levels (Fig. 
1A). FPLC was subsequently employed to determine the sub-class of lipoproteins which 
was affected by vagotomy. Lipid measurements revealed that there was a significant 
reduction (three fold) in VLDL-TG content in vagotomized mice while no changes in 
LDL or HDL associated TG was observed. CHOL content in all fractions were 
comparable in both types of mice (Fig. 1B). This suggests that vagotomy primarily 
regulates VLDL-TG metabolism.    
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In order to study the effect of vagotomy on postprandial hyperlipidemia, the mice were 
subjected to acute oral fat load of olive oil (200µl) and plasma TG and CHOL were 
measured. Plasma TG was significantly reduced in vagotomized mice whereas no 
changes were observed in plasma CHOL levels (Fig. 2A). Immunoblotting analyses of 
plasma proteins showed significant reduction in the levels of apoB48, the structural 
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Fig. 1:  Disruption of sub-diaphragmatic vagal signaling inhibits circulatory TG. Both 
sham and vagotomized mice were fed chow diet and blood was drawn from both the 
groups at the age of 12 weeks in fasted and fed states, and used for the following 
analyses (A) TG and CHOL contents in the plasma of sham and sub-diaphragmatic 
vagotomized (Vag) mice. (B) FPLC plasma fractions showing TG and CHOL contents in 
the sham and vagotomized mice. Results are shown as mean+ SEM, n=4-7/group. 
*P<0.05 and **P<0.01 versus control. 
 
17 
 
 
protein component of intestinal chylomicrons, which suggests that vagotomy inhibits the 
secretion of intestinal TG-rich lipoproteins (TRL) resulting in decreased postprandial 
lipemia (Fig. 2B). These findings indicate that vagotomy decrease hyperlipidemia by 
regulating TG-rich lipoprotein metabolism.       
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3.1.2 Sub-Diaphragmatic Vagotomy Prevents HFD-Induced Hyperlipidemia and 
Hepatic Steatosis. 
Two cohorts of sham and vagotomized mice were fed a HFD diet for 22 weeks to study 
the impact of vagotomy on HFD induced obesity and hyperlipidemia. Plasma TG at week 
0, 12, 20, and 22 was significantly decreased in vagotomized mice compared to sham 
mice. There were no changes in plasma CHOL among both the mice types (Fig. 3A).  In 
order to assess the impact of vagotomy on HFD-induced hepatic steatosis, the lipid 
content in the liver was measured in both sham and vagotomized mice. Hepatic TG was 
significantly reduced in vagotomized mice compared to sham controls, with no 
differences in CHOL (Fig. 3B). All these results suggest vagotomoy can prevent 
hyperlipidemia and hepatic steatosis induced by HFD.      
 
 
Fig. 2:  Disruption of sub-diaphragmatic vagal signaling protects mice from HFD-
induced hyperlipidemia. Both sham and vagotomized mice were subjected to acute 
oral fat load of olive oil (200µl) following 12 hours of fasting and the plasma was 
used for the following analyses (A) plasma TG and CHOL contents in sham and 
sub-diaphragmatic vagotomized mice. (B) Immunoblotting analysis of plasma 
apoB100, apoB48, and albumin at 1 h after a fat load (200 µl olive oil). Results are 
shown as mean+ SEM, n=4-7/group. *P<0.05 and **P<0.01 versus control. 
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3.1.3 Vagtotomy Inhibits HFD-Diet Induced Hepatic Steatosis via Downregulation 
of Lipogenic Genes. 
Improvement in lipid profile in HFD-fed vagotomized mice encouraged us to investigate 
the changes in hepatic lipid metabolism. We investigated two key genes involved in 
hepatic de novo synthesis viz., SREBP-1, SCD-1 and FASN. The mRNA levels of 
SREBP-1was found to be significantly lower in vagotomized mice compared to sham 
mice (Figure 4A). Furthermore, both mRNA and protein levels of SCD-1 gene were also 
considerably reduced in the liver of chow and HFD-fed vagotomized mice (Fig. 4A and 
4B). Inhibition of SCD-1 possibly reduced OA production resulting in reduced 
availability of lipid for VLDL synthesis. Moreover, HFD could not significantly induce 
mRNA expression of FASN, a key lipogenic gene associated with free fatty acid 
biosynthesis, in vagotomized mice post HFD feeding (Fig. 4A). These observations are 
supported by reduced TG levels in the liver as mentioned in the previous section. These 
findings indicate that vagotomy significantly impairs de novo hepatic lipogeneis resulting 
in reduction in hepatic steatosis.       
Fig. 3:  Sub-diaphragmatic vagotomy prevents HFD-induced hyperlipidemia and 
hepatic steatosis. Sham and vagotomized mice were fed a HFD for 22 weeks. Blood 
and liver were collected for the following analyses. (A) Plasma TG and CHOL in 
sham and vagotomized mice at 0, 12, 20 and 22 after HFD (B) Liver TG and CHOL 
contents from sham and vagotomized mice after 22 weeks of high fat diet feeding. 
Results are shown as mean+ SEM, n=4-7/group. *P<0.05 and **P<0.01 versus 
control. 
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3.1.4 GLP-1 Secretion is Elevated Which Inhibits Hepatic de novo Lipogenesis.   
GLP-1 has been implicated in dyslipidemia improvement via reduced lipoprotein 
production. We investigated the circulatory levels of GLP-1 to determine if it mediates 
the inhibitory effect of vagotomy on hepatic lipid synthesis. GLP-1 levels in the plasma 
were significantly increased in vagotomized mice in both fasted and fed states (Fig. 5A). 
The elevation was found to be more profound in the fed state.  To study the changes in 
GLP-1 in postprandial state, the mice were administered a fat load comprising 200 µl 
olive oil. The fat load elevated the levels of GLP-1 in vagotomized mice 4 and 3 folds 
compared to fasted and fed states, respectively (Fig. 5B). This suggests that GLP-1 is 
significantly elevated in response to nutrient intake in absence of vagal signaling.   
 
 
Fig. 4:  Disruption of sub-diaphragmatic vagus nerve prevents HFD-induced hepatic 
steatosis via down regulation of lipogenic genes. Sham and vagotomized mice were 
fed a HFD for 22 weeks. The liver was collected and used for the following analyses. 
(A) Relative mRNA expression of SCD-1 and FASN in the livers of sham and 
vagotomized mice after 22 days of high fat diet or control chow feeding. (B) 
Immunoblotting analysis of hepatic expression of SCD-1 protein in sham and 
vagotomized mice. Results are shown as mean+ SEM, n=4-7/group. *P<0.05 and 
**P<0.01 versus control. 
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We then performed in vitro studies using rat hepatocytes to determine whether GLP-1 
signaling alone is sufficient to inhibit hepatic lipid synthesis. We treated McA cells, a rat 
hepatoma cell line, with PA (50µM) in the presence or absence of exendin-4 (100 nM), a 
GLP-1 agonist, for 48 h. PA treatment significantly enhanced mRNA expression of 
SREBP-1c, a major transcription factor in hepatic lipid synthesis. Moreover, the 
expression of SCD-1, ACC and FASN, the downstream target genes of SREBP-1c, was 
significantly increased. Exendin-4, on the other hand, inhibited PA-induced expression of 
these lipogenic genes (Fig. 6). These findings were further corroborated by a significant 
reduction of secreted TG from palmitic acid (50 µM)-primary mouse cells when 
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Fig. 5:  Vagotomy significantly elevates GLP-1 in circulation. (A) Plasma GLP-1 
levels in sham and vagotomized mice. (B) Plasma GLP-1 in sham and vagotomized 
mice at the fasted state or 1 h after administering 200 µl olive oil. Results are shown 
as mean+ SEM, n=4-7/group. *P<0.05 and **P<0.01 versus control. 
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incubated with exendin-4. Coincubation with exendin-4 lowered the secreted 
triglycerides almost to the level of the control (Fig. 7). No significant changes in secreted 
cholesterol was observed. Therefore, elevated GLP-1 in vagotomized mice may, at least 
partially, be responsible for reduction in TG.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Fig. 6:  Exendin-4, a GLP-1 agonist, inhibits lipid biosynthesis in hepatocytes in 
vitro. McA cells were treated with palmitic acid (PA) (50 µM) in the presence or 
absence of exendin-4 (100 nM) for 48 h. Relative mRNA expression of SREBP-c, 
FASN, SCD-1 and ACC was quantified in the treated cells by qRT-PCR. Results are 
shown as mean+ SEM, n=4-7/group. *P<0.05 and **P<0.01 versus control. 
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3.1.5: Vagotomy Improves Systemic Glucose Tolerance and Enhances Insulin 
Sensitivity. 
We also investigated if the elevated circulatory GLP-1 in vagotomized mice any effect on 
insulin sensitivity and glucose tolerance as we observed improvement in lipid profiles. 
Oral glucose tolerance test (OGTT) in chow-fed mice revealed that glucose tolerance was 
significantly improved in vagotomized mice as indicated by lower blood glucose levels at 
15, 60, and 90 min post glucose administration (Fig. 8A). Similarly, vagotomy led to 
Fig 7:  Exendin-4, a GLP-1 agonist, inhibits lipid biosynthesis in hepatocytes in 
vitro. Primary hepatocytes were treated with vehicle (0.5% BSA) or palmitic acid 
(PA) (50 µM) with or without exendin-4 (100 nM) for 48 h. TG and CHOL levels in 
the culture media was measured. Results are shown as mean+ SEM, n=4-7/group. 
*P<0.05 and **P<0.01 versus control. 
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improved glucose tolerance in HFD-fed mice indicated by reduced glucose levels at 30, 
60, and 90 minutes after glucose administration. On the contrary, HFD diet led to insulin 
resistance in sham mice exemplified by elevated blood glucose levels within 90 min post 
glucose administration (Fig. 7B). Insulin sensitivity was evidently improved in HFD-fed 
vagotomized mice.   
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To investigate the effect of vagotomy on insulin sensitivity in molecular levels, we 
investigated insulin signaling molecules in the liver by immunoblotting. The protein 
expression of the hepatic insulin receptor was found to be significantly increased 
compared to sham control mice (Fig. 9A). Moreover, injection of insulin into hepatic 
portal vein induced more profound activation of AKT, a key component in insulin 
signaling pathway, in vagotomized mice indicating enhanced insulin sensitivity in the 
liver (Fig. 9B). Taken together, these findings suggest that vagotomy improves glucose 
tolerance and insulin sensitivity in HFD-fed mice.       
 
 
 
 
 
Fig. 8:  Vagotomy improves systemic glucose tolerance and enhances hepatic insulin 
sensitivity. (A) Plasma glucose levels in sham and vagotomized mice at 0, 15, 30, 60 
and 90 min after 12 hours of fasting and subsequent oral administration of glucose 
(2g/kg). (B) Plasma glucose levels in sham and vagotomized mice at 0, 15, 30, 60 
and 90 min after 15 weeks of HFD feeding, 12 hours of fasting and subsequent oral 
administration of glucose (2g/kg). Results are shown as mean+ SEM, n=4-7/group. 
*P<0.05 and **P<0.01 versus control. 
A 
Insulin  
Receptor-  
-actin 
Sham Vag 
Liver   MW 
(kDa) 
95- 
42- 
In s u lin  r e c e p to r
0 .0
0 .5
1 .0
1 .5
S h a m
V a g
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 o
f 
th
e
in
d
ic
a
te
d
 p
r
o
te
in
s
 i
n
 l
iv
e
r
*
28 
 
 
 
 
 
 
 
 
  
 
3.2 Fenugreek 
3.2.1 Fenugreek Improved Hyperlipidemia by Inhibiting VLDL Production and 
Secretion. 
We first investigated the effect of fenugreek seeds on hepatic lipid and lipoprotein 
metabolism by quantifying the levels of mRNA expression of genes involved in fatty acid 
β-oxidation. We used CREBH-null mouse model to examine the effect of fenugreek on 
hyperlipidemia. Two groups of mice were fed either a control chow or chow containing 
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Fig. 9:  Vagotomy improves hepatic insulin sensitivity by enhanced expression of 
insulin signaling molecules. (A and B) Immunoblotting analysis of protein levels 
insulin receptor and phosphor-Akt in the livers of sham and vagotomized mice. 
Results are shown as mean+ SEM, n=4-7/group. *P<0.05 and **P<0.01 versus 
control. 
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2% fenugreek seed meal for 7 weeks. The expression of PPARα, and its downstream 
target genes, CPT-1α, Acox-1 and MCAD in the liver was measured by q-RT-PCR. We 
observed significantly enhanced expression of the aforementioned genes in fenugreek-fed 
mice (Fig. 10). This indicates an improvement of fatty acid β-oxidation by fenugreek 
seeds. VLDL assembly and secretion are largely influenced by the availability of lipid 
substrates. Low availability of lipid substrates resulting from inhibition of lipid synthesis 
and augmented fatty acid β-oxidation may lead to lower VLDL synthesis.  
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We then investigated if there were any changes in the plasma VLDL levels as they are 
involved in the transport of lipids from the liver to circulation for distribution to 
peripheral tissues and organs. Fenugreek feeding was also found to significantly reduce 
plasma VLDL levels which was exemplified by the reduced levels of apoB-100 protein in 
the plasma of the fenugreek-fed mice (Fig. 11). There was no change in the levels of 
apoE, another apolipoprotein, suggesting that fenugreek’s inhibitory effect was primarily 
executed on VLDL-TG and VLDL-apoB metabolism (Fig. 11). The overall findings of 
this investigation suggest that fenugreek seed inhibited hepatic VLDL synthesis and 
secretion leading to ameliorated hyperlipidemia in the CREBH-null mice.   
 
 
 
 
Fig. 10: Fenugreek seed improves hyperlipidemia by increased β-oxidation and 
VLDL synthesis. Two groups (n=5-6/group) of CREBH-null mice were subjected to 
chow diet with or without 2% fenugreek for 7 weeks. Plasma and livers were 
collected following 12 hours of fasting for the following analysis. Relative mRNA 
expression of PPARα, CPT-1α, Acox-1 and MCAD in the mouse liver was measured 
by q-RT-PCR. Results are shown as mean+ SEM, n=5-6/group. *P<0.05 and 
**P<0.01 versus controls.     
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3.2.2 Fenugreek inhibits hepatic SREBP-1c activity via enhanced Insig-1 and Insig-2 
expression.  
Depletion of CREBH in CREBH-null mice has been found to induce hepatic steatosis 
and hyperlipidemia via hyperactivation of SREBP-1c and hepatic de novo lipogenesis 
resulting from reduced Insig-2a expression [73]. The CREBH-null mouse model was, 
therefore, used in the present study to investigate the anti-hyperlipidemic effect of 
apoB100 
albumin 
KO/Veh KO/Fenu 
apoE 
Plasmas 
Fig. 11: Fenugreek seed improves hyperlipidemia by increased β-oxidation and VLDL 
synthesis. Two groups (n=5-6/group) of CREBH-null mice were subjected to chow diet 
with or without 2% fenugreek for 7 weeks. Plasmas were collected following 12 hours of 
fasting and used for immunoblotting. Immunoblot developed for apoB100 and apoE and 
immunoblots were quantified.  Results are shown as mean+ SEM, n=5-6/group. *P<0.05 
and **P<0.01 versus controls.     
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fenugreek. The mRNA expression studies via RT-qPCR showed that fenugreek 
significantly induced the expression of Insig-1 and Insig -2b in the mouse liver compared 
to control mice (Fig. 12) This indicates as possibility of reduction in levels active of 
SREBP-1 as its activation is hindered by elevated Insig proteins.  
 
 
 
 
 
 
 
We followed up the investigation on transcription of Insig proteins with examining the 
impact of fenugreek seeds on SREBP signaling pathway. SREBP-1c mRNA expression 
studies showed no significant difference between the fenugreek-fed and the control mice 
(Fig. 13A). This suggests that fenugreek feeding has no influence on SREBP signaling 
Fig 12: Fenugreek seed consumption enhanced Insig-1 and Insig-2 expression.  Two groups 
(n=5-6/group) of CREBH-null mice were subjected to chow diet with or without 2% 
fenugreek for 7 weeks. Livers were collected following 12 hours of fasting and used for the 
analysis of relative mRNA expression of Insig-1 and Insg-2 by q-RT-PCR.  Results are 
shown as mean+ SEM, n=5-6/group. *P<0.05 and **P<0.01 versus controls.     
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pathway, at least in the transcriptional level. Immunoblotting studies, however, revealed 
that fenugreek seed consumption reduced activation of SREBP-1c by proteolytic 
cleavage, indicated by reduced active form of SREBP-1c (N-terminal of SREBP-1) in the 
fenugreek-fed mice. SREBP-2 activation also showed a similar trend of reduction, but the 
change was not statistically significant (Fig. 13B). These observations were consistent 
with increased transcription of Insig-1 and -2., which may retain the SREBP-1c on the 
ER and prevent its activation by hindering translocation to Golgi apparatus    
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We subsequently investigated the effect of inhibition of SREBP-1c activation on the 
mRNA expression of its target genes associated with hepatic lipid synthesis. The mRNA 
expression of the enzymes FASN, and SCD-1 was significantly reduced in fenugreek-fed 
mice (Fig. 14). This is consistent with the inhibition of SREBP-1c activation by Inig-1 
and -2 hyperactiavtion. These findings further substantiate the possible inhibitory effect 
of fenugreek on de novo lipid synthesis in the liver. All these findings suggest that 
consumption of 2% fenugreek prevents SREBP-1c inhibition and hepatic de novo lipid 
synthesis by upregulation of Insig-1 and Insig-2.   
 
 
 
 
 
 
Fig. 13: Fenugreek seed inhibits activation of SREBP-1c.  Two groups (n=5-6/group) of 
CREBH-null mice were subjected to chow diet with or without 2% fenugreek for 7 weeks. 
Livers were collected following 12 hours of fasting and used for the following analyses. (A) 
mRNA expression of SREBP-1c in the liver. (B) Immunoblotting analysis of n-terminal 
SREBP-1c and SREBP-2. Results are shown as mean+ SEM, n=5-6/group. *P<0.05 and 
**P<0.01 versus controls.     
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3.2.3 Trigonelline Inhibits Hepatic Lipid Secretion.  
Trigonelline is one of the major chemical components in fenugreek seeds. We 
employed cell-based culture systems to investigate if trigonelline is one of the 
bioactive compounds responsible for beneficial effect of fenugreek on lipid 
metabolism. To examine the effect of trigonelline, McA cells were treated with the 
saturated fatty acid, palmitic acid (PA) with or without coincubation with trigonelline. 
Before treating with PA, McA cells are pretreated with trigonelline (100µM) or mock 
(H2O) for 24 h. The cells were subsequently incubated with PA (250µM) for an 
additional 6 h. Secretion of TG was significantly reduced in trigonelline treated cells 
(Fig. 15A). However, the CHOL levels were comparable between groups (Figure 
15B). This finding suggests that trigonelline can effectively ameliorate lipotoxicity 
resulting from oxidative stress induced by saturated fatty acid. This also exhibits the 
active role of this bioactive compound in lipid metabolism regulation.  
 
 
Fig. 14: Fenugreek seed hinders mRNA expression of enzymes involved in de novo 
lipid synthesis.  Two groups (n=5-6/group) of CREBH-null mice were subjected to 
chow diet with or without 2% fenugreek for 7 weeks. Livers were collected 
following 12 hours of fasting and livers were collected. Liver samples were used for 
analysis of relative mRNA expression of FASN, ACC and SCD-1. Results are 
shown as mean+ SEM, n=5-6/group. *P<0.05 and **P<0.01 versus controls.     
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Fig. 15: Trigonelline protects from hyperlipidemia by reducing plasma TG levels. 
McA cells were treated with 100 μM of trigonelline for 24 h followed a 12 h fast. 
Cells were then treated with vehicle (BSA) or PA at the presence of mock (H2O) or 
trigonelline (100M) for additional 6 h. The media were collected for lipid 
extraction as descripted in Materials and Methods and used to measure (A) secreted 
TG, and (B) Secreted CHOL. For in vitro study, the data represent one out of three 
independent experiments (n=6/group). Results are shown as mean ± SEM. *P < 
0.05 and **P < 0.01 versus controls. 
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Chapter IV: Discussion 
The goal of the vagotomy study was to delineate the underlying mechanism of sub-
diaphragmatic vagotomy in obesity, hyperlipidemia and insulin resistance prevention. We 
demonstrated that complete disruption of the afferent and efferent fibers of the adnominal 
vagus nerve significantly decreases fasting and postprandial TG levels and VLDL 
biogenesis. Vagotomy also leads to elevated circulatory GLP-1 levels which may result 
in reduced hepatic fatty acid synthesis and VLDL production. HFD-induced hepatic 
steatosis and hyperlipidemia were also ameliorated after surgical removal of the vagus 
nerve. The vagotomized mice also exhibited improved hepatic insulin sensitivity and 
whole body glucose tolerance.  
The autonomic nervous system has been implicated in the regulation of hepatic energy 
metabolism based on certain evidences. Increased vagal nerve activity by portal or jejunal 
infusion of lipids indicates possible role of vagus nerve in transmission of hepatic signals 
to the CNS [75]. Besides, infusion of long-chain fatty acids into hepatic portal vein 
increased hypertension [76, 77], and elevated circulatory epinephrine and norepinephrine 
[78], which suggests CNS activity in response to the infusion [79]. Vagus nerve has been 
reported to suppress systemic inflammation, modulate CNS responses to glucose and 
fatty acids, and regulate insulin sensitivity and hypertension [79-81]. The complete 
disruption of sub-diaphragmatic vagus nerve enabled us to study the local regulation of 
intrinsic gut-liver circuit in the absence of CNS regulation.  We observed significant 
reduction in circulatory and hepatic TG levels in vagotomized mice. This reduction can 
be attributed to elevated GLP-1 levels since we demonstrated that GLP-1 can sufficiently 
downregulate genes involved in hepatic lipid synthesis, including SCD-1 and FASN, in 
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vitro. The in vivo reduction in SCD-1 and FASN can, therefore, be linked to increased 
GLP-1 levels in circulation. Reduced hepatic lipid synthesis in vagotomized mice led to 
less availability of lipid substrates for VLDL assembly, which essentially reduction 
VLDL secretion and prevented HFD-induced hyperlipidemia. Taher et al. reported 
significant reduction in diet-induced VLDL overproduction and dyslipidemia when 
exendin-4 was intraperitoneally injected into Syrian golden hamster [82]. We also 
observed significant improvements in insulin sensitivity and glucose tolerance in 
vagotomized mice. 
Bariatric surgery is an effective clinical procedure to cut down body weight and treat 
obesity related metabolic diseases [83]. A significant loss in weight is observed after the 
surgery which is believed to be due to increased secretion of gut peptides, especially 
GLP-1 [84, 85]. It is hypothesized that direct delivery of ingested food to distal gut after 
the gastric banding procedure leads to increased GLP-1 secretion from the L-cells [86]. 
One explanation of the facilitation of weight loss by GLP-1 is due to its ability to enhance 
satiety and delay gastric emptying [87, 88]. Another explanation of the action of GLP-1 is 
its ability to enhance insulin secretion by the pancreas [88]. We observed a significant 
increase in the circulatory levels of GLP-1 in vagotomized mice, which possibly 
ameliorated hyperlipidemia evident from reduced plasma TG and VLDL secretion.  
Fenugreek has been traditionally used in different parts of the world for treatments of 
various human disorders, including diabetes and hypertension, besides its use as a spice 
and condiment in a variety of food preparations. However, the exact molecular 
mechanism underlying its medicinal properties has not yet been completely delineated. 
The lack of scientific evidence has limited the use of this important dietary plant as a 
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reliable source of phytoceutical. In the current study, we demonstrated that the whole 
grain of fenugreek and its derived bioactive compound, trigonelline prevented 
hyperlipidemia upregulating expression of Insig proteins, inhibiting hepatic VLDL 
biogenesis, and enhancing fatty acid β-oxidation,  
Hyperlipidemia is one major risk factor in the pathogenesis of cardiovascular disease and 
metabolic disorders [89]. Overproduction of VLDL particles is often recognized as 
contributor of hyperlipidic conditions [90]. Boban et al. observed a decrease in VLDL 
biosynthesis and secretion when mice were fed galactomannon extracted from fenugreek 
[91]. Similarly, Naidu et al. reported decrease in plasma triglycerides and restoration of 
VLDL-C to near normal levels by administering diosgenin extracted from fenugreek to 
HFD-streptozotocin (HFD/STZ)-induced diabetic rats [89]. Sharma et al. reported a 
significant decrease in VLDL-TG in type I diabetic patients when administered a diet 
containing fenugreek seed powder [92]. However, the underlying molecular mechanism 
of fenugreek action on VLDL metabolism remained ambiguous. A fiber cocktail 
containing fenugreek seed powder reportedly ameliorated hyperlipidemia in rats through 
enhanced clearance of VLDL particles from plasma by upregulation of apo B, E receptors 
in hepatocytes [93]. In our study, we observed a significant reduction in apoB100, the 
primary apolipoprotein in VLDL, in the plasma of fenugreek-fed mice while no 
considerable alteration in apoE levels was noticed. This observation suggests the 
beneficial effects of fenugreek through regulation of VLDL assembly and secretion. We 
also observed improvement in lipid metabolism demonstrated by reduced secretion of TG 
in trigonelline-treated rat hepatoma cells. Hamden et al. observed a significant decrease 
in serum TG when trigonelline was administered to diabetic rats [94]. Similarly, a 
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significant reduction in TG in diabetic rats was observed by Zhou et al. [95]. All these 
observations indicate beneficial effects of fenugreek seeds and trigonelline administration 
in controlling hyperlipidemia.              
SREBPs are a family of transcription factors that control the expression of an array of 
enzymes for biosynthesis of cholesterol, fatty acids, and TG in hepatocytes [95-97]. 
SREBP activation is regulated by Insig (Insig1 and Insig2) and SCAP proteins within the 
ER membrane [98, 99]. The sterol-sensitive SCAP is associated with inactive SREBP on 
one side and with Insig on the other [100]. When cholesterol is abundant in ER 
membranes, SCAP undergoes a conformational changes enabling the binding between 
SCAP and Insig. This binding prevents the translocation of SCAP-SREBP complex to 
Golgi complex essential for SREBP activation. Low sterol levels lead to conformational 
changes in the SCAP, which leads to dissociation of SCAP-SREBP complex from Insig 
proteins [97, 101]. The SCAP-SREBP complex subsequently translocate to Golgi 
apparatus, where SREBP is cleaved by Site-1 protease (S1P) and Site-2 protease. The N-
terminal domain generated by proteolysis leaves the membrane and moves to the nucleus, 
where it enhances transcription of genes required for de novo lipogenesis [101, 102]. 
Upregulation of SREBPs, especially SREBP-1c, has been recongnized to play a central 
role in the development and progression of metabolic syndrome. This warrants 
development of strategies to reduce the activity of SREBP-1c as a potential treatment 
[103]. Chemical inhibitors have been successfully used to hider SREBP activation. 
However, naturally occurring bioactive compounds which can interfere in SREBP 
activation is of great interest as chemical inhibitor may induce certain side effects. Our 
present study showed that administration of fenugreek seed inhibited activation of 
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SREBP-1c signaling by upregulating Insig1 and Insig2. This consequently reduced de 
novo lipogenesis and VLDL secretion from hepatocytes leading to improved 
hyperlipidemia in CREBH-null mice. It was previously reported that betulin, a triterpene 
isolated from birch bark, can inhibit the activation of SREBPs by inducing interaction 
between SCAP and Insig1 [104]. This inhibitory action of betulin resulted in decline in 
cholesterol and fatty acid biosynthesis thereby ameliorating HFD-induced obesity and 
improving insulin sensitivity. In another report, genistein, a phytochemical in soy, 
suppressed lipogenic gene expression in HepG2 cells via downregulation of S1P 
expression, which subsequently hindered proteolytic activation of SREBP-1 [105]. 
However, more studies are required to delineate the precise mechanism of fenugreek 
seeds on SREBP activation and fatty acid biosynthesis.   
The novel findings from our study suggest that vagotomy can ameliorate HFD-induced 
hyperlipidemia, and improve insulin sensitivity. This study provides insights into 
developing vagotomy-based clinical approaches to treat metabolic disorders like diabetes 
and obesity. Our study also provided an insight into the mechanism of TG-lowering 
activity of fenugreek which alleviates hyperlipidemia. Observations from the fenugreek 
study would advance our understanding of the role of fenugreek in regulation of lipid 
metabolism and help conceive possible therapeutic implications. This study provides a 
rationale to develop of neutraceuticals from fenugreek seeds to treat metabolic disorders.   
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